Collaboration Agreement (Details) $ / shares in Units, $ in Thousands		1 Months Ended			12 Months Ended
	Dec. 10, 2021 USD ($) $ / shares shares	Jan. 31, 2022 USD ($)	Dec. 31, 2021 USD ($) target program	Jul. 31, 2020 USD ($)	Dec. 31, 2021 USD ($) target program	Dec. 31, 2020 USD ($)	Dec. 01, 2021 USD ($)	Jun. 30, 2021 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative
Upfront payment received				$ 15,000	$ 15,000
Revenue					1,319	$ 430
Collaboration receivable			$ 300,000		300,000	0
Deferred revenue, current			$ 28,317		$ 28,317	2,024
Scenario, Adjustment
Collaborative Arrangement and Arrangement Other than Collaborative
Deferred revenue, current								$ 1,900
Eli Lilly
Collaborative Arrangement and Arrangement Other than Collaborative
Number of additional targets | target			3
Number of programs | program			6		6
Number of targets | target			5		5
Difference between fair value of shares and contract price			$ 37,800
Revenue					$ 600
Deferred revenue			337,200		337,200		$ 337,800
Eli Lilly | Share Purchase Agreement
Collaborative Arrangement and Arrangement Other than Collaborative
Sale of stock, number of shares issued in transaction (in shares) | shares	4,000,000
Sale of stock issue price per share (in dollars per share) | $ / shares	$ 20.00
Sale of stock consideration received on the transaction	$ 80,000
Eli Lilly | Subsequent Event
Collaborative Arrangement and Arrangement Other than Collaborative
Upfront payment received		$ 300,000
Merck
Collaborative Arrangement and Arrangement Other than Collaborative
Revenue					700
Deferred revenue			15,000		15,000
Unsatisfied portion of the performance obligation						$ 13,900
Maximum | Sales based
Collaborative Arrangement and Arrangement Other than Collaborative
Amount receivable for achievement of milestones					165,000
Research Development And Regulatory | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative
Amount receivable for achievement of milestones					$ 245,000
Research Development And Regulatory | Maximum | Eli Lilly
Collaborative Arrangement and Arrangement Other than Collaborative
Amount receivable for achievement of milestones			10,000
Amounts receivable for opt out milestones			70,000
Sales Based Milestone | Eli Lilly
Collaborative Arrangement and Arrangement Other than Collaborative
Amount receivable for achievement of milestones			180,000
Amounts receivable for opt out milestones			$ 360,000